ClinicalTrials.gg
Not yet recruitingNCT06338163POSSIBLEUpdated Apr 4, 2024

Polihexanide SSIs Measures Bundle (PSMB) During Enhanced Recovery After Major Digestive Surgery

A Phase 4 interventional study of Polihexanide-based bundle and Standard bundle in Surgical Site Infection and Surgical Procedures, Operative, sponsored by Marco Catarci. Not yet recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Marco Catarci · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Surgical Wound Infection with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Surgical Wound Infection · Italy.

Planned enrollment
Largest of 13
2,000 · median 196
Started
2024
the only one that year
Phase 4
3 of 20
1 open now
Registered
18th of 20
by date

Among the 20 studies in Surgical Wound Infection with a site in Italy, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 4, and was the 18th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

3 of the 20 studies in Surgical Wound Infection with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Surgical Wound Infection with a site in Italy, or all of them as a file.
02

Study summary

This is a randomized controlled, prospective, multicenter superiority trial with two parallel treatment groups and single blinding (local investigators performing postoperative follow up will be blinded for group allocation), with prospective enrollment planned from July 2024 to June 2025 in 20 Italian surgical centers. All patients undergoing elective major gastro-intestinal (GI) tract surgery (upper GI, HPB, \& lower GI) will be included in a prospective database after written informed consent. A total of 2,000 patients is expected based on a mean of 100 cases per center.

Read the detailed description

Just after signing a written informed consent to participate, patients will randomly be assigned either to the experimental group (Polihexanide bundle) or to the control group. Block randomization (blocks of 10 patients per single participating center) will be performed using an unstratified computer generated randomization list. All operations will be performed according to local criteria of the participating center. Hair removal will be accomplished on the day of surgery with electronic clippers. Alcohol-based solutions of chlorhexidine for surgical site skin preparation will be used. A first dose of perioperative i.v. antibiotics will be administered 30 minutes before skin incision (choice of the antibiotic according to local criteria) in all patients. Additional intraoperative doses will be administered for procedures exceeding two half-lives of the antibiotic. At the end of the operation, the peritoneal cavity will be rinsed routinely with 0.9% sodium chloride solution (normal saline, NS) at body temperature. Before closure of fascia, instruments and gloves will be changed. The eventual placement of drain(s) in the peritoneal cavity and/or creation of an intestinal stoma will be recorded. No subcutaneous suture or drainage will be done. Skin will be closed with either staples, intracutaneous running suture or interrupted sutures.

Potential patient-specific and intraoperative risk factors will be recorded: sex, age, body mass index, nutritional status, frailty, indication to surgery (benign vs. malignant disease), perioperative administration of steroids, renal failure and dialysis, cardiovascular or respiratory disease, American Society of Anesthesiologist class, bowel preparation, type of approach, operative time, presence of peritoneal cavity drainage. During the postoperative period, patients will be examined by the attending surgeon daily. Fever (central temperature > 38 °C), pulse, abdominal signs, bowel movements, volume and aspect of drainage (if present) will be recorded daily. The local attending surgeon will make any decision for complementary exams and imaging according to his own criteria. The rate of any adverse event will be calculated and graded according to the Clavien-Dindo criteria [19] and to Japan Clinical Oncology Group Postoperative Complications (JCOG-PC) extended criteria [20], including all anastomotic leaks, wound infection (according to the definitions of the Centers for Disease Control and Prevention and wound culture), pneumonia (clinical symptoms, and physical and radiological examinations), central venous line infection (positive blood culture), urinary tract infection (positive urine culture with bacterial count). ERAS pathway items will be defined according to national [27] guidelines, measuring adherence upon explicit criteria. All data will be recorded for a minimum of 8 weeks (60 days) after surgery. PROM questionnaires will be administered to all enrolled patients four to one week before the planned operation, at discharge, and 6 to 8 weeks after the operation.

After anonymization, all data of each single case will be prospectively uploaded by local investigator(s) on a web-based database, protected by individual access credentials, and incorporated into a spreadsheet for data analysis. Any eventual discrepancy and/or mismatch will be checked, addressed and solved through strict cooperation between coordinating and local investigators.

03

Conditions studied

  • Surgical Site Infection
  • Surgical Procedures, Operative

Keywords

  • surgical site infection
  • polihexanide
  • preoperative decontamination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients submitted to laparoscopic/robotic/open/converted major digestive surgery (upper and lower gastrointestinal resections).
  • ' (ASA) class I, II, III or IV
  • Elective surgery
  • Patients' written acceptance to be included in the study.

Exclusion criteria

Exclusion Criteria:

  • ' (ASA) class V
  • Urgent surgery
  • Pregnancy
  • Hyperthermic intraperitoneal chemotherapy for carcinomatosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Treatment

    Once a day starting 5 days before the operation: Total body washing with usual soap/shampoo and single-use washcloths impregnated with a mix of Polihexanide, surfactants, and excipients. Nasal cleaning 3 times a day with a Polihexanide Nasal Gel Oral gargles 3 times a day using 10 mL of a Polihexanide oral solution. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) of antiseptic solution will be performed using a 0.04% sterile Polihexanide solution. After the end of the application time, a subcutaneous swab for culture will be taken. Before standard (according to local center clinical practice) wound(s) dressing(s), a 3 mm-thick antiseptic gel (a combination comprised of 0.1 % Polihexanide and 0.1 % propyl betaine (surfactant) that is used for cleansing, moistening and decontamination of post-operative wounds) will be applied on any wound(s).

    Combination Product: Polihexanide-based bundle

  • Active comparator
    Control

    Once a day starting 5 days before the operation: Total body washing with usual soap/shampoo. No oral and nasal MDRO-decolonization will be performed. After the closure of fascia, 10 minutes subcutaneous irrigation with 50 to 250 mL (according to incision length) NS will be performed. After the end of the application time, a subcutaneous swab for culture will be taken. Finally, standard wound(s) dressing(s) (according to local center clinical practice) will be applied.

    Combination Product: Standard bundle

Interventions

  • Combination productPolihexanide-based bundle

    Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products

    Also known as: Prontoderm® Wipes (B. Braun Medical AG, Sempach, Switzerland), Prontoderm® Nasal Gel (B. Braun Medical AG, Sempach, Switzerland), ProntOral® (B. Braun Medical AG, Sempach, Switzerland), LavaSurge® (B. Braun Medical AG, Sempach, Switzerland)

  • Combination productStandard bundle

    Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution

06

What researchers measure

Primary outcomes

  1. Surgical Site Infections rate

    CDC definition

    Time frame: 60 days after surgery

  2. Incisional (superficial and deep) Surgical Site Infections rate

    CDC definition

    Time frame: 60 days after surgery

  3. Infectious morbidity rates

    SSI + urinary tract infection + pulmonary infection

    Time frame: 60 days after surgery

Secondary outcomes

  1. Anastomotic leakage rates

    According to international consensus

    Time frame: 60 days after surgery

  2. Overall morbidity rates

    Any adverse event

    Time frame: 60 days after surgery

  3. Major morbidity rates

    Any adverse event grade \> II according to Clavien-Dindo

    Time frame: 60 days after surgery

  4. Comprehensive complication index

    According to Slankamenac et al 2013

    Time frame: 60 days after surgery

  5. Overall length of postoperative hospital stay

    inclusive of any unplanned readmission

    Time frame: 60 days after surgery

  6. Readmission rates

    any unplanned readmission after primary discharge

    Time frame: 60 days after surgery

Other outcomes

  1. Patient-reported outcome measures

    MD Anderson Symptom Inventory for Gastrointestinal Surgery

    Time frame: preoperative, at discharge, 60 days after surgery

07

Study locations

3 sites
08

References and documents

Publications

  • Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2. PubMed 19638912 ↗
  • Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, Tsubosa Y, Satoh T, Yokomizo A, Fukuda H, Sasako M. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016 Jun;46(6):668-85. doi: 10.1007/s00595-015-1236-x. Epub 2015 Aug 20. PubMed 26289837 ↗
  • Strobel RM, Leonhardt M, Krochmann A, Neumann K, Speichinger F, Hartmann L, Lee LD, Beyer K, Daum S, Kreis ME, Lauscher JC. Reduction of Postoperative Wound Infections by Antiseptica (RECIPE)?: A Randomized Controlled Trial. Ann Surg. 2020 Jul;272(1):55-64. doi: 10.1097/SLA.0000000000003645. PubMed 31599810 ↗
  • Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, Holm T, Wong WD, Tiret E, Moriya Y, Laurberg S, den Dulk M, van de Velde C, Buchler MW. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery. 2010 Mar;147(3):339-51. doi: 10.1016/j.surg.2009.10.012. Epub 2009 Dec 11. PubMed 20004450 ↗
  • Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, Abbas M, Atema JJ, Gans S, van Rijen M, Boermeester MA, Egger M, Kluytmans J, Pittet D, Solomkin JS; WHO Guidelines Development Group. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016 Dec;16(12):e276-e287. doi: 10.1016/S1473-3099(16)30398-X. Epub 2016 Nov 2. PubMed 27816413 ↗
  • Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, Reinke CE, Morgan S, Solomkin JS, Mazuski JE, Dellinger EP, Itani KMF, Berbari EF, Segreti J, Parvizi J, Blanchard J, Allen G, Kluytmans JAJW, Donlan R, Schecter WP; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017 Aug 1;152(8):784-791. doi: 10.1001/jamasurg.2017.0904. Erratum In: JAMA Surg. 2017 Aug 1;152(8):803. doi: 10.1001/jamasurg.2017.1943. PubMed 28467526 ↗
  • Mueller TC, Loos M, Haller B, Mihaljevic AL, Nitsche U, Wilhelm D, Friess H, Kleeff J, Bader FG. Intra-operative wound irrigation to reduce surgical site infections after abdominal surgery: a systematic review and meta-analysis. Langenbecks Arch Surg. 2015 Feb;400(2):167-81. doi: 10.1007/s00423-015-1279-x. Epub 2015 Feb 14. PubMed 25681239 ↗

Individual participant data

Plan to share: Undecided — complete dataset after study completion will be availble upon request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Jun 2025, 11 months later.

Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 11 months is below that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2024
First posted
Mar 29, 2024
StartEst.
Jul 1, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06338163
Lead sponsor
Marco Catarci
Collaborators
Associazione Chirurghi Ospedalieri Italiani
Responsible party
Marco Catarci (Study Chair, Ospedale Sandro Pertini, Roma) — Sponsor-investigator
First posted
Mar 29, 2024
Start date
Jul 1, 2024 (estimated)
Primary completion
Jun 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Apr 4, 2024

Study contacts

Marco Scatizzi, MD
Contact
marcoscatizzi60@gmail.com
+393492197687
Mario Campli, MD
Contact
segreteria@acoi.it
+393939038353
Marco Catarci, MD, FACS
study chair · Associazione Chirurghi Ospedalieri Italiani
Massimo Sartelli, MD
principal investigator · Ospedale di Macerata

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion